| The examination of extractables and leachables from | | | | 2.1. Safety Thresholds |
| medical products and devices is growing in importance. | | | | The PQRI Leachables and Extractables Working |
| This has arisen from ISO 10993 Standard Biological | | | | Group have recommended two safety evaluation |
| Evaluation of Medical Devices - Part 18 Chemical | | | | thresholds which have been justified from a |
| Characterisation of Materials and also from various | | | | toxicological or safety perspective: |
| guidelines produced by the FDA1,2. These guidelines | | | | · A Safety Concern Threshold (SCT) of 1.5 |
| are concerned with various drug delivery devices, such | | | | µg per day, which is defined as the threshold |
| as meter dose inhalers (MDI) and dry powder inhalers | | | | below which an individual leachable would have a dose |
| (DPI), and cover a wide range of aspects including | | | | so low as to present negligible safety concerns from |
| extractables and leachables from rubber and plastic | | | | carcinogenic and non-carcinogenic toxic effects; |
| components in these devices. | | | | · A Qualification Threshold (QT) of 5 µg per |
| In recent years the PQRIa Leachables and | | | | day, which is defined as the threshold below which a |
| Extractables Working Group has submitted best | | | | given leachable is not considered for safety |
| practice guidelines3 for Extractables and Leachables | | | | qualification (toxicological assessments) unless the |
| Testing to the PQRI Drug Product Technical | | | | leachable presents structure-activity relationship (SAR) |
| Committee and the U.S. Food and Drug Administration. | | | | concerns |
| These guidelines have made an important contribution | | | | These thresholds represent absolute exposures, |
| to Extractables and Leachables Testing of Orally | | | | expressed as total daily intake per day. They need to |
| Inhaled and Nasal Drug Products (OINDP). | | | | be converted into relative amounts expressed as an |
| This paper discusses the importance of Extractables | | | | amount of a particular leachable per drug product or |
| and Leachables testing to Medical and Drug Delivery | | | | extractable per mass of component. This threshold is |
| Devices, firstly considering the testing of inhalation drug | | | | known as the Analytical Evaluation Threshold (AET). |
| delivery devices (OINDP) and then medical devices. | | | | The AET is determined by consideration of the SCT |
| 2. EXTRACTABLES AND LEACHABLES TESTING | | | | and the specific drug product configuration (e.g. total |
| OF OINDP | | | | number of doses in the Drug Product, number of |
| The assessment of Extractables and Leachables in | | | | doses per day, mass of individual components). |
| OINDP, as recommended by the PQRI, has three main | | | | For an extractables from a device component the |
| parts: | | | | AET (µg/g) can be determined using Equation 1: |
| 1. Extractables | | | | The rest of this paper can be viewed from the Rapra |
| 2. Leachables | | | | Limited website by following the link from the home |
| 3. Routine Extraction Testing | | | | page. |
| Each of these stages is guided by various safety | | | | This article is free to republish provided the resource |
| thresholds.a Product Quality Research Institute | | | | information remains intact. |